written by reader $2 covid pharma stock

by chuppy1130 | June 4, 2020 12:33 am

Kyle Dennis touting a $2 pharma stock, heavy insider buying[1] from CEO, upcoming FDA[2] catalyst and heavily shorted.

Endnotes:
  1. insider buying: https://www.stockgumshoe.com/tag/insider-buying/
  2. FDA: https://www.stockgumshoe.com/tag/fda/

Source URL: https://www.stockgumshoe.com/2020/06/microblog-2-covid-pharma-stock/


11 responses to “written by reader $2 covid pharma stock”

  1. jazzroxy says:

    I have been barraged with emails, but have not been able to figure it out…

  2. gkissi says:

    I believe he’s talking about OPK (OPKO HEALTH INC). Here’s a headline I found on briefing.com:
    Opko Health: FDA has authorized OPKO to undertake a Phase 2 trial with RAYALDEE as a treatment for patients with mild-to-moderate COVID-19. Also a search on openinsider.com shows the CEO heavily buying this stock. The current price as at now is $2.20.

    I’m willing to bet this is the stock he’s talking about! But of course this is just my opinion and my own digging after they’ve been pounding me with same emails you’ve been getting.

  3. Germaine Woods says:

    It’s OPK … I just checked the SEC website

  4. mar Lewis says:

    OPKO Health (NASDAQ:OPK) is a highly shorted stock — 24% of its float is sold short. What this means is that institutions and other investors have borrowed almost a quarter of its shares and sold them on the market, in hopes of being able to profit by repurchasing them later at a lower price. The short-sellers are betting the stock will be lower in the future.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.